Autolus Therapeutics Preparing for Financial Results Announcement
Autolus Therapeutics plc (Nasdaq: AUTL), a dynamic biopharmaceutical company engaged in developing advanced programmed T cell therapies, is gearing up to announce its financial results for the fourth quarter and full year of 2024. This announcement will take place before the U.S. markets open on an upcoming Thursday, which highlights the company’s commitment to transparency and stakeholder engagement.
Conference Call to Discuss Financial Performance
Management plans to hold a detailed conference call and webcast at 8:30 am EDT/12:30 pm GMT on the same day. This will not only cover the financial results but will also provide insights into the company's operations and business developments. Pre-registration for the conference call is encouraged, and participants will need a personal PIN, alongside the dial-in numbers, to join the discussion.
Access to Live Webcast and Replay
For those unable to attend the live session, a simultaneous audio webcast will be available, offering a replay afterward. This ensures that all interested parties can catch up on the vital information shared during the call and understand the company's current standing and future directions.
About Autolus Therapeutics
Autolus Therapeutics plc, listed on Nasdaq under the ticker AUTL, stands at the forefront of biopharmaceutical innovation, particularly in the realm of T cell therapies aimed at tackling difficult health challenges, such as cancer and autoimmune diseases. With a suite of proprietary T cell programming technologies, Autolus is not just developing therapies; it’s creating targeted and potent treatments designed to effectively identify and eliminate problematic cells within the body. Notably, the company has achieved approval for its first product, AUCATZYL, and is diligently advancing its pipeline, which includes candidates for various serious health issues, such as hematological malignancies and solid tumors.
Company Contact Information
If you wish to reach out to Autolus, you can do so through their dedicated contacts. For inquiries, you may contact Amanda Cray at +1 617-967-0207 or via email at a.cray@autolus.com. Additionally, Olivia Manser is also available at +44 7780 471 568 and can be reached at o.manser@autolus.com.
Frequently Asked Questions
When will Autolus announce its financial results?
Autolus Therapeutics will announce its financial results before the opening of the U.S. markets on an upcoming Thursday.
How can I participate in the conference call?
Participants need to pre-register to gain access to the conference call, which will be held at 8:30 am EDT/12:30 pm GMT.
Will there be a webcast available?
Yes, a live audio webcast will be provided, along with a replay after the session concludes.
What is AUCATZYL?
AUCATZYL is Autolus’s first FDA-approved product designed to target specific health conditions related to cancer.
Who can I contact for more information?
You can contact Amanda Cray or Olivia Manser via phone or email for any inquiries regarding the company.